Search research articles
Contact Us
Filters
Showing results (101-110 of 155) with videos related to
Page
of 16
Sort By:
Breast Cancer Research : BCR
|
December 24, 2025
Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors
Justine Dutheil, Victor Pereira, Cyril Boisson, et al.
The Lancet. Oncology
|
November 7, 2025
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial
Stefano Kim, Jihane Boustani, Soledad Iseas, et al.
Frontiers in Oncology
|
September 19, 2022
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
Stefano Kim, Jihane Boustani, Dewi Vernerey, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 29, 2024
Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR
Juliette Thariat, Mathieu Bosset, Antoine Falcoz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 14, 2026
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEO
Emeric Boisteau, Alice Boilève, David Tougeron, et al.
JNCI Cancer Spectrum
|
September 29, 2023
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study
Aziz Zaanan, Julie Henriques, Anthony Turpin, et al.
The Lancet. Oncology
|
December 3, 2020
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
Thierry André, Jeffrey Meyerhardt, Timothy Iveson, et al.
International Journal of Cancer
|
June 12, 2020
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer
Cindy Neuzillet, Andrea Casadei-Gardini, Bertrand Brieau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2021
Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a <i>Post Hoc</i> Analysis of the PRODIGE-GERCOR IDEA-France Trial
Julien Taieb, Valérie Taly, Julie Henriques, et al.
Oncoimmunology
|
February 27, 2026
Multidimensional immune profiling uncovers biphasic peripheral T-cell dynamics after chemoradiation in patients with locally advanced head and neck cancer
Benoît Lecoester, Yaoyao Xie, Xushan Sun, et al.
Page
of 16
Search research articles
Search
Showing results (101-110 of 155) with videos related to
Sort By:
Page
of 16
Breast Cancer Research : BCR
|
December 24, 2025
Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors
Justine Dutheil, Victor Pereira, Cyril Boisson, et al.
The Lancet. Oncology
|
November 7, 2025
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial
Stefano Kim, Jihane Boustani, Soledad Iseas, et al.
Frontiers in Oncology
|
September 19, 2022
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
Stefano Kim, Jihane Boustani, Dewi Vernerey, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 29, 2024
Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR
Juliette Thariat, Mathieu Bosset, Antoine Falcoz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 14, 2026
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEO
Emeric Boisteau, Alice Boilève, David Tougeron, et al.
JNCI Cancer Spectrum
|
September 29, 2023
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study
Aziz Zaanan, Julie Henriques, Anthony Turpin, et al.
The Lancet. Oncology
|
December 3, 2020
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
Thierry André, Jeffrey Meyerhardt, Timothy Iveson, et al.
International Journal of Cancer
|
June 12, 2020
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer
Cindy Neuzillet, Andrea Casadei-Gardini, Bertrand Brieau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2021
Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a <i>Post Hoc</i> Analysis of the PRODIGE-GERCOR IDEA-France Trial
Julien Taieb, Valérie Taly, Julie Henriques, et al.
Oncoimmunology
|
February 27, 2026
Multidimensional immune profiling uncovers biphasic peripheral T-cell dynamics after chemoradiation in patients with locally advanced head and neck cancer
Benoît Lecoester, Yaoyao Xie, Xushan Sun, et al.
Page
of 16